Khondrion
CompanyNetherlands
Khondrion develops one asset, in phase 3 (Sonlicromanol in maternally inherited diabetes and deafness). Mostly small molecule acting on Oxidative stress and ROS signalling, oxidative phosphorylation and inflammation; based in Netherlands.
- 1
- Asset
- Furthest
- Phase 3
- 4
- Trials
- 0
- Signals
Pipeline
1Redox-modulating small molecule targeting ROS and maintaining cellular redox balance
Phase 3, Small molecule, Oxidative stress and ROS signalling, Oxidative phosphorylation, maternally inherited diabetes and deafness, mitochondrial diseases
Full company profiles: pipeline, trials, funding and people.
See ProIn the full profile
- Evidence behind the mechanisms3
- Trials4
- Similar companies6
Updated 7 Oct 2026 · 11 sources